ITM Isotope Technologies Munich SE and the Australian Nuclear Science and Technology Organization (ANTSO) are extending their partnership through a further long-term licensing agreement.
Under the terms of the agreement, ANSTO will continue producing n.c.a. Lutetium-177 for the Australian and New Zealand markets, using ITM's production technology. The aim of the partnership is to address the needs of patients, clinicians, and partners alike.
ITM also retains all intellectual property rights to the medical radioisotope. Further details of the agreement were not disclosed.
